NCT03510897 is a Phase 3 clinical trial of teprasiran in Cardiac Surgery, sponsored by Quark Pharmaceuticals.

Who is sponsoring NCT03510897?

NCT03510897 is sponsored by Quark Pharmaceuticals.

What drugs are being tested in NCT03510897?

Interventions in NCT03510897: teprasiran, Placebo.

What condition does NCT03510897 study?

NCT03510897 studies Cardiac Surgery.

Is NCT03510897 still recruiting?

NCT03510897 is currently terminated. Last updated 16 July 2021.

Last reviewed 2021-07-16 · How we verify

NCT03510897

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

Terminated Phase 3 Last updated 16 July 2021

What this trial tests

Phase 3 trial testing teprasiran in Cardiac Surgery in 1,043 participants. Terminated before completion.

Timeline

29 June 2018

Primary endpoint
14 October 2020

12 April 2021

Quick facts

Lead sponsor	Quark Pharmaceuticals
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	1,043
Start date	29 June 2018
Primary completion	14 October 2020
Estimated completion	12 April 2021
Sites	104 locations across France, New Zealand, Belgium, Austria, United Kingdom, Germany, Canada, Australia

Drugs / interventions tested

teprasiran — full drug profile →
Placebo

Conditions studied

Cardiac Surgery — all drugs for Cardiac Surgery →

Sponsor

Quark Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Cardiac Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is designed to evaluate QPI-1002 versus placebo for the prevention of Major Adverse Kidney Events (MAKE) in subjects at high risk for acute kidney injury following cardiac surgery. Half of the participants will receive QPI-1002 while the other half will receive placebo.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic siRNA: state of the art.
Hu B, Zhong L, Weng Y, Peng L, et al · · 2020 · cited 991× · PMID 32561705 · DOI 10.1038/s41392-020-0207-x
The growth of siRNA-based therapeutics: Updated clinical studies.
Zhang MM, Bahal R, Rasmussen TP, Manautou JE, et al · · 2021 · cited 366× · PMID 33513339 · DOI 10.1016/j.bcp.2021.114432
Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.
Xie X, Yu T, Li X, Zhang N, et al · · 2023 · cited 246× · PMID 37669923 · DOI 10.1038/s41392-023-01589-z
Exosomal miR-125b-5p deriving from mesenchymal stem cells promotes tubular repair by suppression of p53 in ischemic acute kidney injury.
Cao JY, Wang B, Tang TT, Wen Y, et al · · 2021 · cited 229× · PMID 33859745 · DOI 10.7150/thno.54550
Perioperative Acute Kidney Injury.
Gumbert SD, Kork F, Jackson ML, Vanga N, et al · · 2020 · cited 209× · PMID 31687986 · DOI 10.1097/aln.0000000000002968
Paving the Road for RNA Therapeutics.
Dammes N, Peer D. · · 2020 · cited 159× · PMID 32893005 · DOI 10.1016/j.tips.2020.08.004
The landscape of nanoparticle-based siRNA delivery and therapeutic development.
Moazzam M, Zhang M, Hussain A, Yu X, et al · · 2024 · cited 116× · PMID 38204162 · DOI 10.1016/j.ymthe.2024.01.005
RNA therapy: Are we using the right molecules?
Yu AM, Jian C, Yu AH, Tu MJ. · · 2019 · cited 109× · PMID 30521885 · DOI 10.1016/j.pharmthera.2018.11.011

Verify or expand the search:

Other recruiting trials for Cardiac Surgery

Currently open trials in the same condition.

NCT06968936 — Long-term Outcomes Sub-Study of Preoperative Combined Iron Therapy · NA · recruiting
NCT07417462 — Transversus Thoracic Muscle Plane Block Versus Pectointercostal Fascial Block for Enhanced Recovery After Cardiac Surger · NA · recruiting
NCT07193719 — Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children · Phase 1, PHASE2 · recruiting
NCT07116343 — Intrapleural Ropivacaine Infusion in Cardiac Surgery · Phase 4 · recruiting
NCT07354841 — Safety and Performance Evaluation of CPB Venous and Arterial Cannulas · NA · recruiting

Other Quark Pharmaceuticals trials

Trials by the same sponsor.

NCT04654221 — Evaluation of Renal Function in Subjects Who Had Undergone Cardiac Surgery · terminated
NCT02610296 — QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant · Phase 3 · completed
NCT02341560 — Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Isc · Phase 2, PHASE3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03510897 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Quark Pharmaceuticals
Last refreshed: 16 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03510897.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing